Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Heterologous Prime-Boost SARS-CoV-2 Vaccination in Healthy Thai Adolescents
TCTR20210923012Phase 2Completed
- Sponsor
- National Vaccine Institute
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of RH109 in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Primary endpoints: Safety and Immunogenicity. Started Oct 2021; status: completed.
02
Drugs
RH109
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210923012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210923012.